OBJECTIVES: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris. METHODS: One-hundred and six elderly patients with unstable angina pectoris were enrolled and divided into group A (n=55) and group B (n=51). Under the same treatment for angina pectoris, patients in groups A and B were administered with 5 mg and 10 mg of rosuvastatin orally once every night, respectively. The two groups were compared in terms of hemorheology, coagulation indices and immune reaction (serum hs-CRP and IL-6 levels), changes of clinical indices, electrocardiograph (ECG), therapeutic effect, and incidence of adverse reactions. Serum hs-CRP and IL-6 levels were detected by ELISA method, and their correlation was analyzed by Pearson method. RESULTS: Whole blood viscosity at high cut (BVH), whole blood viscosity at low cut (BVL), plasma viscosity (PV), and erythrocyte sedimentation rate (ESR), immunoglobulin index, and the hs-CRP and IL-6 levels decreased in both groups after treatment and were lower in group B than in group A (P<0.05). Prothrombin time (PT) and activated partial thromboplastin time (APTT) increased, while fibrinogen (FIB) decreased in both groups after treatment (P<0.05). Group B was superior to group A in the onset times of myocardial ischemia and angina pectoris, the total duration of myocardial ischemia, and the total effective rate indicated by ECG (P<0.05). No statistical difference was observed in the incidence of adverse reactions between the two groups after treatment (P>0.05). CONCLUSIONS: The optimal efficacy of rosuvastatin at 10 mg/day was higher than that of rosuvastatin at 5 mg/day. AJTR
OBJECTIVES: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris. METHODS: One-hundred and six elderly patients with unstable angina pectoris were enrolled and divided into group A (n=55) and group B (n=51). Under the same treatment for angina pectoris, patients in groups A and B were administered with 5 mg and 10 mg of rosuvastatin orally once every night, respectively. The two groups were compared in terms of hemorheology, coagulation indices and immune reaction (serum hs-CRP and IL-6 levels), changes of clinical indices, electrocardiograph (ECG), therapeutic effect, and incidence of adverse reactions. Serum hs-CRP and IL-6 levels were detected by ELISA method, and their correlation was analyzed by Pearson method. RESULTS: Whole blood viscosity at high cut (BVH), whole blood viscosity at low cut (BVL), plasma viscosity (PV), and erythrocyte sedimentation rate (ESR), immunoglobulin index, and the hs-CRP and IL-6 levels decreased in both groups after treatment and were lower in group B than in group A (P<0.05). Prothrombin time (PT) and activated partial thromboplastin time (APTT) increased, while fibrinogen (FIB) decreased in both groups after treatment (P<0.05). Group B was superior to group A in the onset times of myocardial ischemia and angina pectoris, the total duration of myocardial ischemia, and the total effective rate indicated by ECG (P<0.05). No statistical difference was observed in the incidence of adverse reactions between the two groups after treatment (P>0.05). CONCLUSIONS: The optimal efficacy of rosuvastatin at 10 mg/day was higher than that of rosuvastatin at 5 mg/day. AJTR